1 / 1

Reprinted with permission from the American Society of Clinical Oncology.

michelle-grant
Download Presentation

Reprinted with permission from the American Society of Clinical Oncology.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Figure 3 CALGB (Cancer and Leukemia Group B) 9221: Fatigue, dyspnea, and physical functioning, as recorded on the EORTC (European Organization for Research and Treatment of Cancer) questionnaire, of patients with myelodysplastic syndrome who crossed over from supportive care to treatment with azacitidine (5-Aza-C) (n = 30) Reprinted with permission from the American Society of Clinical Oncology. Silverman LR and Mufti GJ (2005) Methylation inhibitor therapy in the treatment of myelodysplastic syndrome Nat Clin Pract Oncol 2: S12–S22 doi:10.1038/ncponc0347

More Related